ArticleBlood advances2021

Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.

Justin Anthony Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.